Skip to main content
Top
Published in: Acta Diabetologica 1/2018

01-01-2018 | Original Article

Arterial-ventricular coupling in type 1 diabetes: arterial stiffness is associated with impaired global longitudinal strain in type 1 diabetes patients—the Thousand & 1 Study

Authors: Simone Theilade, Peter Rossing, Jan S. Jensen, Magnus T. Jensen

Published in: Acta Diabetologica | Issue 1/2018

Login to get access

Abstract

Aims

Diabetes is associated with higher arterial stiffness—an early marker of cardiovascular disease. The coupling between arterial stiffness and myocardial function is still unresolved. We investigate associations between arterial stiffness and early myocardial impairment assessed with advanced echocardiography.

Methods

In 305 type 1 diabetes (T1D) patients without known heart disease and with normal left ventricular ejection fraction (LVEF) (biplane LVEF > 45%), we measured arterial stiffness as pulse wave velocity (PWV) and performed conventional and speckle-tracking echocardiography assessing global longitudinal strain (GLS) as a measure of systolic myocardial function. Associations between PWV and myocardial function were reported as standardized beta values from adjusted regression models including age, sex, mean arterial pressure, body mass index, HbA1c, diabetes duration, estimated glomerular filtration rate, degree of albuminuria, total cholesterol, heart rate and smoking.

Results

Patients were 54 (12) years [mean (SD)], 152 (50%) females, diabetes duration 31 (16) years, HbA1c 65 (12) mmol/mol, LVEF 58 (5) %, GLS −18.2 (2.6) % and PWV 10.2 (3.4) m/s. There was no association between PWV and LVEF (p = 0.93). Conversely, there was a highly significant association between PWV and GLS in crude and multivariable models (standardized β-coefficient 0.25, p < 0.001 and 0.16, p = 0.036, respectively). Also, diastolic function measured as E/e′ was highly associated with PWV in crude and multivariable models (standardized β-coefficient 0.43, p < 0.001 and 0.17, p = 0.016, respectively).

Conclusions

In T1D patients with normal LVEF and without known heart disease, higher arterial stiffness is independently associated with early systolic and diastolic myocardial impairment detectable by advanced echocardiography. Although unable to demonstrate causality, we display a relationship between diabetic angiopathy and diabetic cardiomyopathy (H-3-2009-139 and PROFIL-H-B-2009-056).
Literature
1.
go back to reference Matteucci E, Giampietro O (2014) Epidemiology of cardiovascular disease in patients with type 1 diabetes: European perspective. Exp Clin Endocrinol Diabetes 122:208–214CrossRefPubMed Matteucci E, Giampietro O (2014) Epidemiology of cardiovascular disease in patients with type 1 diabetes: European perspective. Exp Clin Endocrinol Diabetes 122:208–214CrossRefPubMed
2.
go back to reference Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H (2001) Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 44(Suppl 2):S14–S21CrossRefPubMed Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H (2001) Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 44(Suppl 2):S14–S21CrossRefPubMed
3.
go back to reference Orchard TJ, Costacou T, Kretowski A, Nesto RW (2006) Type 1 diabetes and coronary artery disease. Diabetes Care 29:2528–2538CrossRefPubMed Orchard TJ, Costacou T, Kretowski A, Nesto RW (2006) Type 1 diabetes and coronary artery disease. Diabetes Care 29:2528–2538CrossRefPubMed
4.
go back to reference Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234CrossRefPubMed Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234CrossRefPubMed
5.
go back to reference Black JA, Sharp SJ, Wareham NJ et al (2014) Does early intensive multifactorial therapy reduce modelled cardiovascular risk in individuals with screen-detected diabetes? Results from the ADDITION-Europe cluster randomized trial. Diabetes Med 31:647–656CrossRef Black JA, Sharp SJ, Wareham NJ et al (2014) Does early intensive multifactorial therapy reduce modelled cardiovascular risk in individuals with screen-detected diabetes? Results from the ADDITION-Europe cluster randomized trial. Diabetes Med 31:647–656CrossRef
6.
go back to reference Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591CrossRefPubMed Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591CrossRefPubMed
7.
go back to reference Aso Y, Inukai T, Tayama K, Takemura Y (2000) Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 37:87–92CrossRefPubMed Aso Y, Inukai T, Tayama K, Takemura Y (2000) Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 37:87–92CrossRefPubMed
8.
9.
go back to reference Llaurado G, Ceperuelo-Mallafre V, Vilardell C et al (2014) Advanced glycation end products are associated with arterial stiffness in type 1 diabetes. J Endocrinol 221:405–413CrossRefPubMed Llaurado G, Ceperuelo-Mallafre V, Vilardell C et al (2014) Advanced glycation end products are associated with arterial stiffness in type 1 diabetes. J Endocrinol 221:405–413CrossRefPubMed
10.
go back to reference Persson M, Ostling G, Smith G et al (2014) Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease. Stroke 45:18–23CrossRefPubMed Persson M, Ostling G, Smith G et al (2014) Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease. Stroke 45:18–23CrossRefPubMed
11.
12.
go back to reference Hammes HP (2003) Pathophysiological mechanisms of diabetic angiopathy. J Diabetes Complicat 17:16–19CrossRefPubMed Hammes HP (2003) Pathophysiological mechanisms of diabetic angiopathy. J Diabetes Complicat 17:16–19CrossRefPubMed
13.
go back to reference Kals J, Kampus P, Kals M et al (2008) Inflammation and oxidative stress are associated differently with endothelial function and arterial stiffness in healthy subjects and in patients with atherosclerosis. Scand J Clin Lab Invest 68:594–601CrossRefPubMed Kals J, Kampus P, Kals M et al (2008) Inflammation and oxidative stress are associated differently with endothelial function and arterial stiffness in healthy subjects and in patients with atherosclerosis. Scand J Clin Lab Invest 68:594–601CrossRefPubMed
14.
go back to reference Mitchell GF (2008) Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. J Appl Physiol 105:1652–1660CrossRefPubMedPubMedCentral Mitchell GF (2008) Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. J Appl Physiol 105:1652–1660CrossRefPubMedPubMedCentral
15.
go back to reference Laurent S, Cockcroft J, Van BL et al (2006) Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27:2588–2605CrossRefPubMed Laurent S, Cockcroft J, Van BL et al (2006) Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27:2588–2605CrossRefPubMed
16.
go back to reference Laurent S, Boutouyrie P, Asmar R et al (2001) Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37:1236–1241CrossRefPubMed Laurent S, Boutouyrie P, Asmar R et al (2001) Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37:1236–1241CrossRefPubMed
17.
go back to reference Trika CO, Zakopoulos N, Toumanidis ST, Stamatelopoulos SF, Moulopoulos SD (2004) Pulse pressure and left ventricular diastolic dysfunction in hypertensive patients. Cardiology 102:108–114CrossRefPubMed Trika CO, Zakopoulos N, Toumanidis ST, Stamatelopoulos SF, Moulopoulos SD (2004) Pulse pressure and left ventricular diastolic dysfunction in hypertensive patients. Cardiology 102:108–114CrossRefPubMed
18.
go back to reference Vlachopoulos C, Aznaouridis K, Stefanadis C (2010) Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 55:1318–1327CrossRefPubMed Vlachopoulos C, Aznaouridis K, Stefanadis C (2010) Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 55:1318–1327CrossRefPubMed
19.
go back to reference Willum-Hansen T, Staessen JA, Torp-Pedersen C et al (2006) Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 113:664–670CrossRefPubMed Willum-Hansen T, Staessen JA, Torp-Pedersen C et al (2006) Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 113:664–670CrossRefPubMed
20.
go back to reference Chan YH, Kuo CT, Wu LS et al (2016) combined global longitudinal strain and intraventricular mechanical dyssynchrony predicts long-term outcome in patients with systolic heart failure. Circ J 80:177–185CrossRefPubMed Chan YH, Kuo CT, Wu LS et al (2016) combined global longitudinal strain and intraventricular mechanical dyssynchrony predicts long-term outcome in patients with systolic heart failure. Circ J 80:177–185CrossRefPubMed
21.
go back to reference Krishnasamy R, Isbel NM, Hawley CM et al (2015) Left ventricular global longitudinal strain (GLS) is a superior predictor of all-cause and cardiovascular mortality when compared to ejection fraction in advanced chronic kidney disease. PLoS ONE 10:e0127044CrossRefPubMedPubMedCentral Krishnasamy R, Isbel NM, Hawley CM et al (2015) Left ventricular global longitudinal strain (GLS) is a superior predictor of all-cause and cardiovascular mortality when compared to ejection fraction in advanced chronic kidney disease. PLoS ONE 10:e0127044CrossRefPubMedPubMedCentral
22.
go back to reference Jensen MT, Sogaard P, Andersen HU et al (2016) Early myocardial impairment in type 1 diabetes patients without known heart disease assessed with tissue Doppler echocardiography: the Thousand & 1 study. Diabetes Vasc Dis Res 13:260–267CrossRef Jensen MT, Sogaard P, Andersen HU et al (2016) Early myocardial impairment in type 1 diabetes patients without known heart disease assessed with tissue Doppler echocardiography: the Thousand & 1 study. Diabetes Vasc Dis Res 13:260–267CrossRef
23.
go back to reference Gorcsan J III, Tanaka H (2011) Echocardiographic assessment of myocardial strain. J Am Coll Cardiol 58:1401–1413CrossRefPubMed Gorcsan J III, Tanaka H (2011) Echocardiographic assessment of myocardial strain. J Am Coll Cardiol 58:1401–1413CrossRefPubMed
24.
go back to reference Jensen MT, Sogaard P, Andersen HU et al (2014) Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study. Diabetologia 57:672–680CrossRefPubMed Jensen MT, Sogaard P, Andersen HU et al (2014) Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study. Diabetologia 57:672–680CrossRefPubMed
25.
go back to reference Jensen MT, Sogaard P, Andersen HU et al (2015) Global longitudinal strain is not impaired in type 1 diabetes patients without albuminuria: the Thousand & 1 Study. JACC Cardiovasc Imaging 8:400–410CrossRefPubMed Jensen MT, Sogaard P, Andersen HU et al (2015) Global longitudinal strain is not impaired in type 1 diabetes patients without albuminuria: the Thousand & 1 Study. JACC Cardiovasc Imaging 8:400–410CrossRefPubMed
26.
go back to reference Theilade S, Rossing P, Eugen-Olsen J, Jensen JS, Jensen MT (2016) suPAR level is associated with myocardial impairment assessed with advanced echocardiography in patients with type 1 diabetes with normal ejection fraction and without known heart disease or end-stage renal disease. Eur J Endocrinol 174:745–753CrossRefPubMed Theilade S, Rossing P, Eugen-Olsen J, Jensen JS, Jensen MT (2016) suPAR level is associated with myocardial impairment assessed with advanced echocardiography in patients with type 1 diabetes with normal ejection fraction and without known heart disease or end-stage renal disease. Eur J Endocrinol 174:745–753CrossRefPubMed
27.
go back to reference Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463CrossRefPubMed Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463CrossRefPubMed
28.
go back to reference Lee DS, Gona P, Vasan RS et al (2009) Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the national heart, lung, and blood institute. Circulation 119:3070–3077CrossRefPubMedPubMedCentral Lee DS, Gona P, Vasan RS et al (2009) Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the national heart, lung, and blood institute. Circulation 119:3070–3077CrossRefPubMedPubMedCentral
29.
go back to reference Solomon SD, Anavekar N, Skali H et al (2005) Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 112:3738–3744CrossRefPubMed Solomon SD, Anavekar N, Skali H et al (2005) Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 112:3738–3744CrossRefPubMed
30.
go back to reference Levey AS, Coresh J, Greene T et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247–254CrossRefPubMed Levey AS, Coresh J, Greene T et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247–254CrossRefPubMed
31.
go back to reference Nagueh SF, Appleton CP, Gillebert TC et al (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 10:165–193CrossRefPubMed Nagueh SF, Appleton CP, Gillebert TC et al (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 10:165–193CrossRefPubMed
32.
go back to reference Kasner M, Westermann D, Steendijk P et al (2007) Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation 116:637–647CrossRefPubMed Kasner M, Westermann D, Steendijk P et al (2007) Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation 116:637–647CrossRefPubMed
33.
go back to reference Van Bortel LM, Laurent S, Boutouyrie P et al (2012) Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 30:445–448CrossRefPubMed Van Bortel LM, Laurent S, Boutouyrie P et al (2012) Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 30:445–448CrossRefPubMed
34.
go back to reference Software Operator’s Guide—Atcor Medical Manual. 2008 Software Operator’s Guide—Atcor Medical Manual. 2008
35.
go back to reference Theilade S, Lajer M, Persson F, Joergensen C, Rossing P (2013) Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes. Diabetes Care 36:715–721CrossRefPubMedPubMedCentral Theilade S, Lajer M, Persson F, Joergensen C, Rossing P (2013) Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes. Diabetes Care 36:715–721CrossRefPubMedPubMedCentral
36.
go back to reference Bell V, McCabe EL, Larson MG et al (2017) Relations between aortic stiffness and left ventricular mechanical function in the community. J Am Heart Assoc 6:e004903CrossRefPubMedPubMedCentral Bell V, McCabe EL, Larson MG et al (2017) Relations between aortic stiffness and left ventricular mechanical function in the community. J Am Heart Assoc 6:e004903CrossRefPubMedPubMedCentral
37.
go back to reference Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG (2002) Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 106:2085–2090CrossRefPubMed Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG (2002) Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 106:2085–2090CrossRefPubMed
38.
go back to reference Schram MT, Henry RM, van Dijk RA et al (2004) Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study. Hypertension 43:176–181CrossRefPubMed Schram MT, Henry RM, van Dijk RA et al (2004) Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study. Hypertension 43:176–181CrossRefPubMed
39.
go back to reference Fang ZY, Prins JB, Marwick TH (2004) Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25:543–567CrossRefPubMed Fang ZY, Prins JB, Marwick TH (2004) Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25:543–567CrossRefPubMed
40.
go back to reference Miki T, Yuda S, Kouzu H, Miura T (2013) Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev 18:149–166CrossRefPubMed Miki T, Yuda S, Kouzu H, Miura T (2013) Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev 18:149–166CrossRefPubMed
41.
go back to reference Zhang X, Chen C (2012) A new insight of mechanisms, diagnosis and treatment of diabetic cardiomyopathy. Endocrine 41:398–409CrossRefPubMed Zhang X, Chen C (2012) A new insight of mechanisms, diagnosis and treatment of diabetic cardiomyopathy. Endocrine 41:398–409CrossRefPubMed
42.
go back to reference Mihm MJ, Seifert JL, Coyle CM, Bauer JA (2001) Diabetes related cardiomyopathy time dependent echocardiographic evaluation in an experimental rat model. Life Sci 69:527–542CrossRefPubMed Mihm MJ, Seifert JL, Coyle CM, Bauer JA (2001) Diabetes related cardiomyopathy time dependent echocardiographic evaluation in an experimental rat model. Life Sci 69:527–542CrossRefPubMed
43.
go back to reference Ernande L, Bergerot C, Rietzschel ER et al (2011) Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy? J Am Soc Echocardiogr 24(1268–1275):e1 Ernande L, Bergerot C, Rietzschel ER et al (2011) Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy? J Am Soc Echocardiogr 24(1268–1275):e1
44.
go back to reference Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE (2008) Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes. J Nephrol 21:566–569PubMed Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE (2008) Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes. J Nephrol 21:566–569PubMed
45.
go back to reference de ZD, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004;110:921-927 de ZD, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004;110:921-927
46.
go back to reference Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL (2002) Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105:2512–2517CrossRefPubMed Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL (2002) Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105:2512–2517CrossRefPubMed
47.
go back to reference Mitsunami K, Inoue S, Maeda K et al (1998) Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. Cardiovasc Drugs Ther 12:469–474CrossRefPubMed Mitsunami K, Inoue S, Maeda K et al (1998) Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. Cardiovasc Drugs Ther 12:469–474CrossRefPubMed
48.
go back to reference Trost SU, Belke DD, Bluhm WF, Meyer M, Swanson E, Dillmann WH (2002) Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 51:1166–1171CrossRefPubMed Trost SU, Belke DD, Bluhm WF, Meyer M, Swanson E, Dillmann WH (2002) Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 51:1166–1171CrossRefPubMed
49.
go back to reference Rosenlund S, Theilade S, Hansen TW, Andersen S, Rossing P (2014) Treatment with continuous subcutaneous insulin infusion is associated with lower arterial stiffness. Acta Diabetol 51:955–962CrossRefPubMed Rosenlund S, Theilade S, Hansen TW, Andersen S, Rossing P (2014) Treatment with continuous subcutaneous insulin infusion is associated with lower arterial stiffness. Acta Diabetol 51:955–962CrossRefPubMed
50.
go back to reference Bakris GL, Molitch M (2014) Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care 37:867–875CrossRefPubMed Bakris GL, Molitch M (2014) Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care 37:867–875CrossRefPubMed
Metadata
Title
Arterial-ventricular coupling in type 1 diabetes: arterial stiffness is associated with impaired global longitudinal strain in type 1 diabetes patients—the Thousand & 1 Study
Authors
Simone Theilade
Peter Rossing
Jan S. Jensen
Magnus T. Jensen
Publication date
01-01-2018
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 1/2018
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-017-1062-2

Other articles of this Issue 1/2018

Acta Diabetologica 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.